188 related articles for article (PubMed ID: 35053556)
1. A Small Molecule-Drug Conjugate (SMDC) Consisting of a Modified Camptothecin Payload Linked to an α
Lerchen HG; Stelte-Ludwig B; Kopitz C; Heroult M; Zubov D; Willuda J; Schlange T; Kahnert A; Wong H; Izumi R; Hamdy A
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053556
[TBL] [Abstract][Full Text] [Related]
2. Discovery of VIP236, an αvβ3-Targeted Small-Molecule-Drug Conjugate with Neutrophil Elastase-Mediated Activation of 7-Ethyl Camptothecin Payload for Treatment of Solid Tumors.
Lerchen HG; Stelte-Ludwig B; Heroult M; Zubov D; Gericke KM; Wong H; Frigault MM; Johnson AJ; Izumi R; Hamdy A
Cancers (Basel); 2023 Sep; 15(17):. PubMed ID: 37686656
[TBL] [Abstract][Full Text] [Related]
3. Neutrophil elastase as a versatile cleavage enzyme for activation of αvβ3 integrin-targeted small molecule drug conjugates with different payload classes in the tumor microenvironment.
Rebstock AS; Wiedmann M; Stelte-Ludwig B; Wong H; Johnson AJ; Izumi R; Hamdy A; Lerchen HG
Front Pharmacol; 2024; 15():1358393. PubMed ID: 38495100
[No Abstract] [Full Text] [Related]
4. Bilirubin Nanoparticle-Assisted Delivery of a Small Molecule-Drug Conjugate for Targeted Cancer Therapy.
Lee S; Lee Y; Kim H; Lee DY; Jon S
Biomacromolecules; 2018 Jun; 19(6):2270-2277. PubMed ID: 29712433
[TBL] [Abstract][Full Text] [Related]
5. Optimizing the enzymatic release of MMAE from
Zambra M; Ranđelović I; Talarico F; Borbély A; Svajda L; Tóvári J; Mező G; Bodero L; Colombo S; Arrigoni F; Fasola E; Gazzola S; Piarulli U
Front Pharmacol; 2023; 14():1215694. PubMed ID: 37492088
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Evaluation of a Non-Peptide Small-Molecule Drug Conjugate Targeting Integrin α
Paulus J; Sewald N
Front Chem; 2022; 10():869639. PubMed ID: 35480387
[TBL] [Abstract][Full Text] [Related]
7. A nanotherapeutic strategy to overcome chemoresistance to irinotecan/7-ethyl-10-hydroxy-camptothecin in colorectal cancer.
Huang Q; Liu X; Wang H; Liu X; Zhang Q; Li K; Chen Y; Zhu Q; Shen Y; Sui M
Acta Biomater; 2022 Jan; 137():262-275. PubMed ID: 34718178
[TBL] [Abstract][Full Text] [Related]
8. A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization.
Hashimoto Y; Koyama K; Kamai Y; Hirotani K; Ogitani Y; Zembutsu A; Abe M; Kaneda Y; Maeda N; Shiose Y; Iguchi T; Ishizaka T; Karibe T; Hayakawa I; Morita K; Nakada T; Nomura T; Wakita K; Kagari T; Abe Y; Murakami M; Ueno S; Agatsuma T
Clin Cancer Res; 2019 Dec; 25(23):7151-7161. PubMed ID: 31471314
[TBL] [Abstract][Full Text] [Related]
9. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.
Ogitani Y; Hagihara K; Oitate M; Naito H; Agatsuma T
Cancer Sci; 2016 Jul; 107(7):1039-46. PubMed ID: 27166974
[TBL] [Abstract][Full Text] [Related]
10. Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model.
Sapra P; Zhao H; Mehlig M; Malaby J; Kraft P; Longley C; Greenberger LM; Horak ID
Clin Cancer Res; 2008 Mar; 14(6):1888-96. PubMed ID: 18347192
[TBL] [Abstract][Full Text] [Related]
11. Enhanced anti-hepatocarcinoma efficacy by GLUT1 targeting and cellular microenvironment-responsive PAMAM-camptothecin conjugate.
Ma P; Sun Y; Chen J; Li H; Zhu H; Gao X; Bi X; Zhang Y
Drug Deliv; 2018 Nov; 25(1):153-165. PubMed ID: 29282992
[TBL] [Abstract][Full Text] [Related]
12. DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance.
Takegawa N; Nonagase Y; Yonesaka K; Sakai K; Maenishi O; Ogitani Y; Tamura T; Nishio K; Nakagawa K; Tsurutani J
Int J Cancer; 2017 Oct; 141(8):1682-1689. PubMed ID: 28677116
[TBL] [Abstract][Full Text] [Related]
13. Lysosomal P-gp-MDR1 Confers Drug Resistance of Brentuximab Vedotin and Its Cytotoxic Payload Monomethyl Auristatin E in Tumor Cells.
Liu-Kreyche P; Shen H; Marino AM; Iyer RA; Humphreys WG; Lai Y
Front Pharmacol; 2019; 10():749. PubMed ID: 31379564
[TBL] [Abstract][Full Text] [Related]
14. Novel Hydrophilic Camptothecin Derivatives Conjugated to Branched Glycerol Trimer Suppress Tumor Growth without Causing Diarrhea in Murine Xenograft Models of Human Lung Cancer.
Tsuchihashi Y; Abe S; Miyamoto L; Tsunematsu H; Izumi T; Hatano A; Okuno H; Yamane M; Yasuoka T; Ikeda Y; Tsuchiya K
Mol Pharm; 2020 Apr; 17(4):1049-1058. PubMed ID: 32068412
[TBL] [Abstract][Full Text] [Related]
15. Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers.
Zhao H; Rubio B; Sapra P; Wu D; Reddy P; Sai P; Martinez A; Gao Y; Lozanguiez Y; Longley C; Greenberger LM; Horak ID
Bioconjug Chem; 2008 Apr; 19(4):849-59. PubMed ID: 18370417
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice.
Schluep T; Cheng J; Khin KT; Davis ME
Cancer Chemother Pharmacol; 2006 May; 57(5):654-62. PubMed ID: 16133526
[TBL] [Abstract][Full Text] [Related]
17. BPRDP056, a novel small molecule drug conjugate specifically targeting phosphatidylserine for cancer therapy.
Chen YY; Lo CF; Chiu TY; Hsu CY; Yeh TK; Chen CP; Huang CL; Huang CY; Wang MH; Huang YC; Ho HH; Chao YS; Shih JC; Tsou LK; Chen CT
Transl Oncol; 2021 Jan; 14(1):100897. PubMed ID: 33069101
[TBL] [Abstract][Full Text] [Related]
18. Biological properties of IDN5174, a new synthetic camptothecin with the open lactone ring.
Beretta GL; Petrangolini G; De Cesare M; Pratesi G; Perego P; Tinelli S; Tortoreto M; Zucchetti M; Frapolli R; Bello E; Manzotti C; Fontana G; Bombardelli E; Battaglia A; Samorì C; Zunino F
Cancer Res; 2006 Nov; 66(22):10976-82. PubMed ID: 17108136
[TBL] [Abstract][Full Text] [Related]
19. Camptothecin conjugated with DNA minor-groove binder netropsin: enhanced lactone stability, inhibition of human DNA topoisomerase I and antiproliferative activity.
Sukhanova A; Grokhovsky S; Zhuze A; Devy J; Pluot M; Oleinikov V; Nabiev I
Anticancer Res; 2003; 23(3B):2609-15. PubMed ID: 12894548
[TBL] [Abstract][Full Text] [Related]
20. Structural Optimization and Enhanced Prodrug-Mediated Delivery Overcomes Camptothecin Resistance in High-Risk Solid Tumors.
Nguyen F; Guan P; Guerrero DT; Kolla V; Naraparaju K; Perry LM; Soberman D; Pressly BB; Alferiev IS; Chorny M; Brodeur GM
Cancer Res; 2020 Oct; 80(19):4258-4265. PubMed ID: 32839252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
